Discussion {#onco12159-sec-0001}
==========

The treatment of metastatic renal cell carcinoma (mRCC) has dramatically changed over the last 10 years with the approval of several drugs that have significantly improved the prognosis of these patients. Everolimus is a mammalian target of rapamycin inhibitor that prolongs progression‐free survival compared to placebo in pretreated patients with mRCC.

Noninfectious pneumonitis (NIP) was reported in up to 19% of patients treated with everolimus in clinical trials; mouth ulcers, stomatitis, and oral mucositis have occurred at an incidence ranging from 44% to 78%. In the literature, grade 2--3 stomatitis and NIP requiring everolimus discontinuation or dose reductions are reported in approximately 25% of cases (15%--16% for stomatitis, 9%--10% for pneumonitis).

Management of NIP consists of dose reduction or drug discontinuation and treatment with corticosteroids. Prednisone has a role in the treatment of recurrent oral aphthae nonresponsive to local corticosteroid therapy.

![Radiologic images. **(A)**: Ground glass areas and reticular opacification in the lower left lobe. Asymptomatic patient (grade 1 NIP). **(B)**: Ground glass opacification in the right upper lobe. Patient hospitalized due to severe dyspnea and fever (grade 3 NIP). **(C)**: Consolidations and ground glass opacification in the lower lobes. Pleural efffusion in both lungs. Patient hospitalized with severe dyspnea and desaturation (grade 3 NIP). **(D)**: Pulmonary consolidation with reticular opacifications in the middle lobe of the right lung; patient with fever and dyspnea (grade 2 NIP).](onco12159-fig-0001){#onco12159-fig-0001}

The rationale of our study was to provide evidence‐based literature on the use of oral prednisone 5 mg b.i.d. associated with everolimus 10 mg/day in mRCC to reduce the incidence and/or the severity of everolimus‐induced NIP and stomatitis.

Our study enrolled eight patients who had previously received at least one previous systemic treatment. Five patients were treated in a second‐line setting and three patients were treated in third line.

At first radiological evaluation after 2 months, three of eight patients (38%) developed NIP and discontinued everolimus (one grade 2 and two grade 3). Infective etiologies were excluded. Radiologic images were reviewed by a radiologist expert in lung pathology. Two of these patients had concomitant progressive disease and one had stable disease. All patients were treated with high‐dose corticosteroids and oxygen as needed. In one further case, a routine computed tomography scan showed drug‐related ground‐glass areas in the lung, although the patient was completely asymptomatic.

Grade 1 mucositis was found only in one case (13%). One patient experienced grade 3 diabetes, and three patients had grade 2 asthenia.

Five patients (63%) experienced disease progression at the first radiological evaluation after a median of 2 months. One patient discontinued study treatment due to drug‐related grade 3 NIP after 2 months of treatment, whereas two patients are continuing treatment free of progression after 12+ months. Four patients of the five with disease progression died. Median overall survival was 11.6 months (95% confidence interval 2.7 to not reached).

In conclusion, we stopped the accrual of the study due to a high incidence of NIP with the impossibility to reach the preplanned target to reduce drug discontinuation to 10%. The results of this study suggest a need to better investigate the real pathogenesis of NIP and to carefully monitor for toxicities in patients treated with everolimus and concomitant chronic corticosteroids taken for any clinical reason.

Trial Information {#onco12159-sec-1801}
=================

**Disease**Renal cell carcinoma---clear cell**Stage of disease/treatment**Metastatic/advanced**Prior therapy**One prior regimen**Type of study ‐ 1**Phase II**Type of study ‐ 2**Single arm**Primary endpoint**Safety**Secondary endpoint**Tolerability**Additional details of endpoints or study design** Incidence of noninfectious pneumonitis and stomatitis is the rate or range of occurrence or influence of these two adverse events related to standard treatment with everolimus. From data reported in literature, the treatment with everolimus induces an incidence of pneumonitis and stomatitis of grade ≥2 of 25%: we assume that the association of everolimus and prednisone will reduce these toxicity events to approximately 10%. Evaluation method: RECIST 1.1. **Investigator\'s Analysis**Poorly tolerated/not feasible

Drug Information for Phase II Control Arm {#onco12159-sec-9301}
=========================================

Drug 1 Generic/working nameEverolimusTrade nameAfinitorCompany nameNovartisDrug typeBiologicalDrug classmTORDose10 milligrams (mg) per flat doseRouteOral (PO)Schedule of administrationEverolimus 10mg daily, oral administrationDrug 2 Generic/working namePrednisoneDrug typeCorticosteroidDose5mg b.i.d. milligrams (mg) per flat doseRouteOral (PO)Schedule of administrationPrednisone 5mg b.i.d., oral administration

Patient Characteristics for Phase II Control Arm {#onco12159-sec-1531}
================================================

**Patient Characteristics for Phase II Control Arm** **Number of patients, male**6**Number of patients, female**2**Stage**Metastatic renal cell carcinoma, stage IV**Age**Median (range): 44--77**Number of prior systemic therapies**Median (range): 2--3**Performance status: ECOG**0 --- 7 1 --- 1 2 --- 0 3 --- 0 unknown ---**Cancer types or histologic subtypes**Clear cell carcinoma, 8

Primary Assessment Method for Phase II Control Arm {#onco12159-sec-1641}
==================================================

Assessment Number of patients screened10Number of patients enrolled8Number of patients evaluable for toxicity8Number of patients evaluated for efficacy8Evaluation methodRECIST 1.1Response assessment CR*n* = 0Response assessment PR*n* = 0Response assessment SD*n* = 2Response assessment PD*n* = 6Response assessment OTHER*n* = 0(Median) duration assessments PFS2 months, 95% CI: 1.8 to not reached(Median) duration assessments OS12 months, 95% CI: 1.8 to not reached

Adverse Events: Phase II Control Arm {#onco12159-sec-1701}
====================================

imageJohn Wiley & Sons, Ltd.[^1][^2]

Serious Adverse Events {#onco12159-sec-2101}
======================

imageJohn Wiley & Sons, Ltd.

Assessment, Analysis, and Discussion {#onco12159-sec-1101}
====================================

CompletionStudy terminated before completionTerminated reasonToxicityPharmacokinetics/PharmacodynamicsNot collectedInvestigator\'s AssessmentPoorly tolerated/not feasible

 {#onco12159-sec-0002}

The treatment of metastatic renal cell carcinoma (mRCC) has dramatically changed over the last 10 years with the approval of several drugs that have significantly improved the prognosis of these patients. Most of them are tyrosine kinases inhibitors (TKIs), such as sunitinib, pazopanib, axitinib, sorafenib, cabozantinib, and lenvatinib. Some of them are mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and temsirolimus, and a newly approved agent, nivolumab, is an immune checkpoint inhibitor \[[1](#onco12159-bib-0001){ref-type="ref"}\], \[[2](#onco12159-bib-0002){ref-type="ref"}\], \[[3](#onco12159-bib-0003){ref-type="ref"}\], \[[4](#onco12159-bib-0004){ref-type="ref"}\], \[[5](#onco12159-bib-0005){ref-type="ref"}\], \[[6](#onco12159-bib-0006){ref-type="ref"}\], \[[7](#onco12159-bib-0007){ref-type="ref"}\], \[[8](#onco12159-bib-0008){ref-type="ref"}\], \[[9](#onco12159-bib-0009){ref-type="ref"}\].

Everolimus is an mTOR inhibitor that prolongs progression‐free survival compared with placebo in pretreated patients with mRCC \[[7](#onco12159-bib-0007){ref-type="ref"}\]; it is actually also approved for treatment of advanced hormone receptor‐positive, human epidermal growth receptor 2‐negative breast cancer, along with exemestane, in postmenopausal women and for treatment of advanced gastrointestinal, pancreatic, and lung neuroendocrine tumors \[[10](#onco12159-bib-0010){ref-type="ref"}\], \[[11](#onco12159-bib-0011){ref-type="ref"}\], \[[12](#onco12159-bib-0012){ref-type="ref"}\].

Noninfectious pneumonitis (NIP) is a nonmalignant infiltration of the lungs and is a class effect of mTOR inhibitors such as everolimus and temsirolimus. In the investigator brochure, NIP was reported in up to 19% of patients treated with everolimus \[[13](#onco12159-bib-0013){ref-type="ref"}\]. In a phase III study by Motzer et al., NIP was reported in 14% of patients, but a reanalysis of this study\'s chest imaging reported clinical pneumonitis in 13.5% but also radiological evidence of pneumonitis in 39% of patients on everolimus \[[14](#onco12159-bib-0014){ref-type="ref"}\], \[[15](#onco12159-bib-0015){ref-type="ref"}\]. The mechanism by which mTOR inhibitors induce NIP is not well understood.

Clinical findings of NIP are quite varied. Patients may be completely asymptomatic or have nonspecific respiratory symptoms, such as cough, dyspnea, and hypoxia. Fever may be present, making differential diagnosis from bacterial pneumonia even more difficult. The most typical radiographic changes observed with mTOR inhibitor‐associated pneumonitis are ground‐glass areas and focal consolidations \[[16](#onco12159-bib-0016){ref-type="ref"}\].

Stomatitis is an inflammation of mucosal surfaces of the oral cavity, often associated with erythema, edema, burning sensation, and occasionally bleeding \[[17](#onco12159-bib-0017){ref-type="ref"}\]. In the RECORD‐1 trial, the incidence of stomatitis in the everolimus arm was 42%, and 3% of cases were grade 3. The investigator brochure reports that mouth ulcers, stomatitis, and oral mucositis have occurred at an incidence ranging from 44% to 78% of patients treated with everolimus \[[13](#onco12159-bib-0013){ref-type="ref"}\].

In the literature, grade 2--3 stomatitis and NIP requiring everolimus discontinuation or dose reduction are reported in approximately 25% of cases (15%--16% for stomatitis, 9%--10% for pneumonitis) \[[13](#onco12159-bib-0013){ref-type="ref"}\].

Management of NIP consists of dose reduction or drug discontinuation and the use of corticosteroids. Prednisone has a role in the treatment of recurrent oral aphthae nonresponsive to local corticosteroid therapy \[[18](#onco12159-bib-0018){ref-type="ref"}\], \[[19](#onco12159-bib-0019){ref-type="ref"}\].

Prednisone at low doses is considered a week inducer of CYP3A4; however, no data on the influence of prednisone on everolimus trough levels are available \[[13](#onco12159-bib-0013){ref-type="ref"}\].

We designed a proof‐of principle open‐label, single‐arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/day in patients with mRCC who had disease progression following at least one prior vascular endothelial growth factor receptor TKI. The study was designed to enroll 42 patients. The rationale for our study was to provide evidence‐based literature on the use of prednisone associated with everolimus in mRCC to reduce the incidence and/or the severity of everolimus‐induced NIP and stomatitis. As a parameter of efficacy, we sought a reduction in the incidence of NIP to 10% due to the combination of everolimus and prednisone.

Our study enrolled eight patients treated with everolimus for mRCC pretreated with at least one previous systemic treatment. All patients were treated for stage IV renal cell carcinoma. Histology was clear cell carcinoma for all patients. Five patients were treated with everolimus after one previous TKI (sunitinib in four cases and pazopanib in one case), and three patients were treated in third line after two previous lines (sunitinib‐axitinib, sunitinib‐cabozantinib, and pazopanib‐nivolumab). Patients were treated according to clinical practice until disease progression or unacceptable toxicity occurred. Compliance to the treatment was optimal. Toxicities were evaluated and registered according to the National Cancer Institute Common Toxicity Criteria version 4.0.

At first radiological evaluation after a median of 56 days (range 53--58), three of eight patients (38%) developed NIP and discontinued everolimus (one grade 2 and two grade 3). Infective etiologies were excluded. Radiologic images were reviewed by a radiologist expert in lung pathology. Two of these patients had concomitant progressive disease and one had stable disease. All patients were treated with high‐dose corticosteroids and oxygen as needed. In one further case, a routine computed tomography scan showed drug‐related ground‐glass areas, but the patient was completely asymptomatic, so no specific treatment was administered. This patient underwent disease progression at the first evaluation, and treatment was discontinued.

Grade 1 mucositis was found only in one case (13%), and it was resolved in few days without additional treatments. Regarding other toxicities, one patient experienced grade 3 diabetes, and three patients experience grade 2 fatigue.

Five patients (63%) experienced disease progression at the first radiological evaluation after a median of 2 months. One patient discontinued study treatment due to drug‐related grade 3 NIP after 2 months of treatment with stable disease, whereas two patients are still continuing treatment free of progression after 12+ months. Four patients among the five with disease progression have died. Median overall survival is 11.6 months (95% confidence interval 2.7 to not reached).

The study was stopped due to a high incidence of NIP with the impossibility to reach the preplanned target to reduce drug discontinuation to 10%.

In conclusion, the results of this study suggest better investigating the real pathogenesis of NIP and carefully monitoring for toxicities in patients treated with everolimus and concomitant chronic corticosteroids taken for any clinical reason. The low incidence of mucositis may suggest a protective role of systemic corticosteroids, but further studies are necessary.
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[^1]: Maximum Common Terminology Criteria for Adverse Events grade adverse events reported during the treatment with everolimus plus prednisone.

[^2]: Abbreviations: NC/NA, no change from baseline/no adverse event.
